In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
<i>Acinetobacter baumannii</i> is currently classified as one of six pathogens that contribute to increased patient mortality. Thus, exploratory studies navigating alternative treatment strategies are of supreme interest. Herein, we completed minimum inhibitory concentration (MIC) testin...
Saved in:
Main Authors: | Jacinda C. Abdul-Mutakabbir (Author), Juwon Yim (Author), Logan Nguyen (Author), Philip T. Maassen (Author), Kyle Stamper (Author), Zain Shiekh (Author), Razieh Kebriaei (Author), Ryan K. Shields (Author), Mariana Castanheira (Author), Keith S. Kaye (Author), Michael J. Rybak (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> Pneumonia
by: Jae-Min Park, et al.
Published: (2021) -
Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of <i>Staphylococcus aureus</i> in a Pharmacokinetic/Pharmacodynamic Model
by: Jacinda C. Abdul-Mutakabbir, et al.
Published: (2020) -
Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant <i>Klebsiella Pneumoniae</i>: Exploring A Colistin Sparing Protocol
by: Manawr AL-Quraini, et al.
Published: (2022) -
First Description of Colistin and Tigecycline-Resistant <i>Acinetobacter baumannii</i> Producing KPC-3 Carbapenemase in Portugal
by: Cátia Caneiras, et al.
Published: (2018) -
Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models of <i>Escherichia coli</i> and <i>Acinetobacter baumannii</i>
by: Soraya Herrera-Espejo, et al.
Published: (2024)